Back in April, the U.S. Drug Enforcement Administration announced it would be reviewing the possibility of changing the federal classification of marijuana from Schedule 1 to Schedule 2.
Marijuana is currently listed among the DEA’s Schedule 1 drugs, which it describes as “most dangerous” and having “a high potential for abuse.” Other Schedule 1 drugs include heroin and LSD.
Schedule 2 drugs include legal prescription drugs like Ritalin and Adderal.
A re-scheduling of marijuana would clear the regulatory path for medical marijuana research and could be another step toward federal marijuana legalization.
Last week, the Santa Monica Observer reported the DEA will be making marijuana a Schedule 2 drug on August 1. The report cited an anonymous DEA lawyer with knowledge on the matter.
However, this week aNewDomain interviewed DEA staff coordinator Russ Baer, who didn’t confirm the Santa Monica Observer report.
“We want to remove the roadblocks for research,” Baer said. He noted that GW Pharmaceuticals PLC- ADR GWPH 6.54% is “showing some great preliminary results with CBD.”
Cannabidiol (CBD) is one of 113 active cannabinoids found in marijuana.
Despite the commitment to research, Baer added that the DEA is “not holding ourselves to any artificial timeline.”
He also noted marijuana isn’t a top priority for the agency, which is primarily focused on the nation’s growing opioid crisis.
“The potential DEA ruling likely doesn’t do much beyond encouraging more research into cannabis risks and benefits and make it perhaps easier for universities to get involved and for commercial entities to raise capital,” industry expert Alan Brochstein told Benzinga. “I don’t expect the DEA to reschedule cannabis but think it might do something with respect to CBD.”
So far in 2016, marijuana stocks have been…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
